Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience
Uri Kopylov1, Irit Avni-Biron2, Yulia Ron3, Benjamin Koslowsky4, Matti Waterman5, Saleh Daher6, Bella Ungar1, Doron Schwartz7, Eran Zittan8, Michal Openhaim9, Henit Yanai2, Nitsan Maharshak3, Ariella Bar Gil Shitrit4, Timna Naftali9, Rami Eliakim1, Yehuda Chowers5, Shomron Ben-Horin1, Iris Dotan2
1Department of Gastroenterology, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
2Division of Gastroenterology, Rabin Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
4Digestive Diseases Institute, Shaare Zedek Medical Center, Affiliated with the Faculty of Medicine, Hebrew University, Jerusalem, Israel
5Department of Gastroenterology, Rambam Healthcare Campus, Affiliated with the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
6Department of Gastroenterology, Hadassah Medical Center, Affiliated with the Faculty of Medicine, Hebrew University, Jerusalem, Israel
7Department of Gastroenterology, Soroka Medical Center, Affiliated with the Faculty of Medicine, Ben Gurion University, Beer Sheva, Israel
8Department of Gastroenterology, Haemek Medical Center, Affiliated with the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
9Department of Gastroenterology, Meir Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Digestive and Liver Disease
Tập 51
68-74
Thông tin tác giả